Jinling Pharmaceutical Company Limited (SHE:000919)

SHE:000919 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	1,323	1,771	1,548	1,495	1,502	1,316
Short-Term Investments	236.02	165.22	337.45	250	-	-
Trading Asset Securities	1,042	706.05	233.86	92.35	1.25	1.38
Cash & Short-Term Investments	2,601	2,642	2,119	1,837	1,503	1,317
Cash Growth	19.86%	24.69%	15.33%	22.25%	14.12%	-16.44%
Accounts Receivable	767.31	686.73	591.05	467.22	507.2	488.79
Other Receivables	7.91	8.16	8.76	53.12	16.85	6.38
Receivables	775.23	694.89	599.81	520.34	524.05	495.17
Inventory	250.84	271.62	290.91	250.48	245.48	215.44
Prepaid Expenses	-	-	0.15	1.16	-	4.35
Other Current Assets	24.27	9.37	9.63	23.79	16.29	15.13
Total Current Assets	3,652	3,618	3,020	2,633	2,289	2,047
Property, Plant & Equipment	1,505	1,501	1,541	1,303	1,297	1,307
Long-Term Investments	59.04	431.07	369.32	265.01	638.97	674.37
Goodwill	62.42	62.42	148.72	27.33	18.05	64.01
Other Intangible Assets	321.94	325.67	341.67	258.44	140.2	148.18
Long-Term Deferred Tax Assets	15.83	12.49	16.61	28.54	19.62	14.95
Long-Term Deferred Charges	87.46	83.34	13.94	18.26	17.85	4.89
Other Long-Term Assets	354.57	54.49	42	10.7	26.96	22.9
Total Assets	6,058	6,089	5,493	4,544	4,448	4,284
Accounts Payable	597.77	595.31	546.69	454.04	479.36	465.79
Accrued Expenses	57.14	212.46	224.73	219.95	207.27	164.74
Short-Term Debt	-	-	-	1.48	15.01	-
Current Portion of Leases	2.77	4.23	3.08	1.53	1.06	-
Current Income Taxes Payable	56.46	35.53	37.97	48.38	43.09	36.62
Current Unearned Revenue	21.92	35.6	17.65	22.14	26.9	30.67
Other Current Liabilities	230.04	143.9	182.53	117.9	83.25	101.75
Total Current Liabilities	966.09	1,027	1,013	865.42	855.95	799.57
Long-Term Debt	150.12	150.12	-	-	-	-
Long-Term Leases	36.7	34.85	38.6	2.29	0.59	-
Long-Term Unearned Revenue	0.96	1	0.47	0.63	0.79	1.27
Long-Term Deferred Tax Liabilities	30.83	27.28	28.72	48.98	55.77	49.58
Total Liabilities	1,185	1,240	1,080	917.32	913.1	850.43
Common Stock	623.71	623.71	511.14	510.4	504	504
Additional Paid-In Capital	1,098	1,098	651.74	478.34	462.06	462.06
Retained Earnings	2,096	2,073	2,095	2,025	1,958	1,888
Treasury Stock	-6.77	-6.77	-26.99	-23.62	-	-
Comprehensive Income & Other	3.04	3.09	3.42	4.17	3.29	3.29
Total Common Equity	3,814	3,791	3,234	2,994	2,928	2,857
Minority Interest	1,060	1,057	1,178	632.88	606.84	575.68
Shareholders' Equity	4,874	4,849	4,412	3,627	3,535	3,433
Total Liabilities & Equity	6,058	6,089	5,493	4,544	4,448	4,284
Total Debt	189.59	189.21	41.67	5.3	16.66	-
Net Cash (Debt)	2,412	2,453	2,077	1,832	1,486	1,317
Net Cash Growth	11.38%	18.08%	13.39%	23.26%	12.85%	-16.44%
Net Cash Per Share	3.89	4.14	4.12	3.64	2.95	2.61
Filing Date Shares Outstanding	623.71	623.71	629.06	488.88	510.4	504
Total Common Shares Outstanding	623.71	623.71	511.14	488.88	504	504
Working Capital	2,686	2,591	2,007	1,768	1,433	1,248
Book Value Per Share	6.12	6.08	6.33	6.12	5.81	5.67
Tangible Book Value	3,430	3,403	2,744	2,708	2,769	2,645
Tangible Book Value Per Share	5.50	5.46	5.37	5.54	5.50	5.25
Buildings	-	1,495	1,507	1,294	1,274	1,304
Machinery	-	1,416	1,349	1,114	1,074	1,014
Construction In Progress	-	71.78	84.2	37.84	28.78	16.56

Source: S&P Global Market Intelligence. Standard template. Financial Sources.